Skip to main content
Menu
US

AlphaLISA Human Total PD1 Detection Kit, 500 Assay Points

The AlphaLISA™ Human PD-1 Detection Kit is designed for detection and quantitation of human Programmed Cell Death Protein 1 (PD-1) in cell culture media or serum using a homogeneous (no-wash steps, no separation steps) assay.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Feature Specification
Application Protein Quantification
Dynamic Range 9 - 100,000 pg/mL
Limit of Detection 9 pg/mL  
Limit of Quantification 37 pg/mL  
Sample Volume 5 µL

The AlphaLISA™ Human PD-1 Detection Kit is designed for detection and quantitation of human Programmed Cell Death Protein 1 (PD-1) in cell culture media or serum using a homogeneous (no-wash steps, no separation steps) assay.

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).

Product Variants
Unit Size: 100 Assay Points
Part #:
AL343HV
List Price
USD 1,017.00
Unit Size: 500 Assay Points
Part #:
AL343C
List Price
USD 2,392.00
Unit Size: 5,000 Assay Points
Part #:
AL343F
List Price
USD 15,950.00

Overview

Formats:

  • Our HV (100 assay point) kits allow you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).
  • Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
  • Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

Features:

  • No-wash steps, no separation steps
  • ELISA alternative technology
  • Sensitive detection
  • Broad sample compatibility
  • Small sample volume
  • Results in less than 3 hours
  • Half the time of an ELISA assay

Programmed cell death protein 1 (PD-1), also known as cluster of differentiation 279 (CD279), belongs to immunoglobulin superfamily and is a transmembrane receptor protein. PD-1 is present on T –cells or B-cells and binds to ligands, such as PD-L1 and PD-L2, to down regulate the immune system by modulating many other cytokines and cytokine receptors. Anti PD-1 antibody drugs been shown to enhance the immune systems of several types of cancer patients.

AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Specifications

Application
Protein Quantification
Automation Compatible
Yes
Brand
AlphaLISA
Detection Modality
Alpha
Dynamic Range
9 - 100,000 pg/mL
Limit of Detection
9 pg/mL  
Limit of Quantification
37 pg/mL  
Product Group
Kit
Sample Volume
5 µL
Shipping Conditions
Shipped in Blue Ice
Target
PD-1
Target Class
Biomarkers
Target Species
Human
Technology
Alpha
Therapeutic Area
Oncology
Unit Size
500 Assay Points

Image gallery

Video gallery

Resources

Are you looking for resources, click on the resource type to explore further.

1-2 of 2 Resources
Application Note Icon
Application Note
Protocol optimization for detection and quantification of membrane-bound proteins using AlphaLISA technology

Membrane proteins, which are key in cellular signaling and often serve as disease biomarkers, are a significant focus in research...

Flyer Icon
Flyer
Solutions to advance your CART-T cell research

Chimeric antigen receptor (CAR) T-cell therapy has transformed the field of immuno-oncology providing a novel approach to treating...

Scroll Icon